Summary: Ergothioneine concentrations in the blood of 113 patients with diabetes mellitus and 22 nondiabetic individuals were measured by high performance liquid chromatography. There is no statistically significant difference between the mean ergothioneine concentrations of the diabetic and non-diabetic populations but there are several significant differences within the diabetic population. Male diabetics have a higher ergothioneine concentration than female diabetics. Type II diabetics have a higher ergothioneine concentration than type I diabetics. Diabetics receiving a higher insulin dose have higher ergothioneine concentrations. There was no correlation of ergothioneine concentration with the concentration of haemoglobin AI or with the number of years diabetic. It is suggested that zinc therapy may be beneficial for diabetics having a high concentration of blood ergothioneine.
Introduction
Ergothioneine is the betaine of thiolhistidine which is found ubiquitously in living organisms. It is thought to be biosynthesized only in molds (1), but to accumulate in many organisms as a result of its slow rate of degradation (2) . Ergothioneine can be in bound form (3) in the plasma or liver, but is present in free form (1) (2) (3) in erythrocytes and many-tissues. It has been reported that diabetic patients have a significantly higher concentration of ergothioneine in their erythrocytes (0.127 g/1) than normal individuals (0.096 g/1), with 16% of diabetics exceeding the highest con·ĉ entration (0.177 g/1) found in normal individuals and reaching concentrations as high as 0.60 g/1 (4) . This elevation of ergothioneine concentrations is not just a result of the diabetic state, since no rise in ergothioneine concentrations is observed in rats made diabetic with alloxan (5) . However, depancreatized rats have decreased red blood cell ergothioneine, suggesting a relationship between pancreatic function and ergothioneine pharmacodynamics (5) . Ergothioneine concentrations have also been associated with the formation of cataracts, since cataractous human lens has a lower ergothioneine content than normal lens (6) . The possible role of ergothioneine in health and disease has received little attention (7) . One of the chemical properties of ergothioneine which suggests that it might have biological effects is its ability to form complexes with divalent metal ions (8) , although it would generally bind less metal ions than glutathione (9) . It has been suggested that the chelation properties of ergothioneine could be important in the development of diabetes mellitus (10) . Trace metals can regulate insulin release (11) as well as having insulin-like action (12) in the whole animal. Several studies have shown effects of ergothioneine on biological systems both in vitro and in vivo. Ergothioneine inhibits the degradation of insulin by a liver extract (13) . It inhibits the activity of polyphenol oxidases (8) , papain (14) and the ATPase activity of myosin in the absence of divalent cations (14) . Ergothioneine inhibits lipid peroxidation in mouse liver homogenates (15) . It accelerates the oxidation of reduced nicotinamide adenine dinucleotide by metmyoglobin or methaemoglobin (16) . Ergothioneine also accelerates lactate formation in red blood cells (17) and reduced the pentobarbital sleeping time and inhibited hepatic injury (18) . Ergothioneine protects against cadmium-induced teratogenesis (19) .
Because of the variety of biological effects that have been demonstrated for ergothioneine and because of the previous association that had been demonstrated between blood ergothioneine concentrations and diabetes mellitus (4), it was decided to investigate this relationship further. In the original work of Fr ser, a colorimetric method based on the diazotization of ergothioneine was used (4) . Recently, with the development of high performance liquid chromatography (HPLC) 1 , a more specific and sensitive method for the determination of ergothioneine became available (2) . We have used HPLC methodology to determine ergothioneine concentrations, primarily in diabetics, and evaluated if there is a correlation between these concentrations and other indices such as age, sex, haemoglobin Aj (HbAi) concentrations and class of diabetes.
Methods
Human blood specimens, which had been taken for diagnostic purposes, were used. The blood samples were collected in vacutainers with EDTA as anticoagulant. Glycosylated haemoglobin (HbAO was determined by the Isolab microcolumn procedure (20) . For ergothioneine determinations the blood samples were diluted 1:3 with distilled water, placed in a boiling water bath for 15 minutes and then centrifuged for 15 minutes at top speed in a clinical centrifuge. A measured aliquot of variable volume of the supernate was withdrawn and lyophilized. The dried residue was taken up in aqueous ethanol, volume fraction 0.5, and filtered through a 0.2 micron Gelman Aero LC13 filter assembly. Twenty to 100 μΐ were injected onto a 4 χ 300 mm μ Bondapak NH 2 column with a guard column containing Bondapak AX/Corasil (Waters Associates, Milford, MA). The column was eluted with acetonitrile and water (80 + 20 by volume). A Varian Model 5560 HPLC instrument, fitted with a UV-200 scanning detector and a Model 8085 auto sampler, was used. The detector was set at 258 nm (the absorbance maximum of ergothioneine), and the How rate set at 1 ml/min. Ergothioneine was eluted at about 18 min as a distinct peak, well resolved from other peaks in the chromatograms. After the complete elution of ergothioneine, the acetonitrile, water (80 + 20 by volume) mixture was run for an additional 15 minutes to wash the column. After a number of runs, the column was washed with acetonitrile in water, volume fraction 0.5 and/or with pure acetonitrile followed by re-equilibration with the acetonitrile, water (80 + 20 by volume). A standard curve with 0.1 to 2 μg of ergothioneine (Sigma Chem. Co., St. Louis, MO) was made and found to l?e linear. This standard curve was used to calculate the amount of ergothioneine in our samples using the Varian 4270 integrator. Quantitative recovery (> 95%) of ergothioneine from aqueous solutions or added to blood samples was found after boiling, lyophilizing and redissolving in aqueous ethanol, volume fraction 0.5. Similar results were found by Mayumi et al. (2) , after whose work our method was adapted.
Statistical analysis was performed on an IBM-PC computer using the PC Statistician software package (Human Systems Dynamics, Northridge, CA). Frequency distributions were first obtained. Ergothioneine concentrations for diabetics do not follow a normal distribution. Statistical significance was evaluated using the non-parametric Mann-Whitney U test for this group but the Student t-test for the non-diabetic population which showed a normal distribution. The precision of our ergothioneine determinations by HPLC is within ± 10%. 
Results
The frequency distribution of the blood ergothioneine concentrations of diabetic individuals shows a nonnormal distribution ( fig. 1 ). is no correlation with sex for the smaller non-diabetic population. When the diabetic population is separated into type I and type II and males are compared with females for each of these groups the sex difference is no longer statistically significant (p > 0.05). However, type II males have higher ergothioneine concentrations than type I males but this is not the case for type I vs type II females (tab. 1). There is no significant difference between diabetic vs non-diabetic males, diabetic vs non-diabetic females or type II diabetic males vs non-diabetic males (p > 0.05). Type II diabetics also have ergothioneine concentrations which are higher than those of type I diabetics (tab. 1). The HbAj concentrations for all of the groups of diabetics are significantly above the average expected for normal individuals and by approximately the same amount (tab. 1). The data for the entire diabetic population were further analyzed by a least-squares linear regression analysis to find the correlation between ergothioneine concentrations and other variables (tab. 2). There was a weak correlation between ergothioneine concentrations and either insulin dose or age which showed some statistical significance. This was further analyzed by comparing different groups of subjects using the Mann-Whitney U test. Diabetics below the age of 20 had lower ergothioneine concentrations than older diabetics although there was no significant difference among diabetics in the 20-40, 40-60 and 60 and above age groups nor was there an age dependence for the smaller non-diabetic population. All but one of the diabetics in the 0-20 age group was a type I diabetic. We have already shown that type I diabetics have a lower ergothioneine concentration than type II diabetics (tab. 1). There is no statistically significant difference between type I diabetics below the age of 20 compared to type I diabetics above the age of 20. Therefore, the correlation of ergothioneine concentration with age for diabetics is at least partially a consequence of the difference between type I and type II diabetics. Diabetics receiving less than 40 units of insulin per day had lower ergothioneine concentrations than those receiving larger insulin doses (tab. 1). The group receiving the lower insulin dose did not have a statistically significant difference in their mean HbAi concentration, age or sex compared with the group receiving the higher insulin dosage (all are type I diabetics). 
